Sunday, Apr 22 2018 | Time 18:05 Hrs(IST)
image
image image
  • Death toll from Afghan blast reaches 48 - official
  • Once DMK assumes power, present Ministers will be in jail: Stalin
  • Attempts are being made to disintegrate country: Rajnath
  • Marketing Federation purchase over 1 20 MT of mustard in Haryana
  • Five govt procuring agencies & traders purchase over 65 08 lakh MT of wheat
  • Iraq's April 19 air strike in Syria killed 36 IS militants -spokesman
  • Police burst IPL betting racket with arrest of 3 , seize electronic items
  • Calling students ‘rowdies’ unacceptable, revoke order closing tuition centres in Kashmir: AIP Prez
  • Day temp above normal in Eastern India, some parts of Mah, Goa and south west
  • Session on Transgenic & Medicinal plants organised at Agriculture Dept of Aryans Group
  • PM interacts with BJP MPs, MLAs through Narendra Modi App
  • Rahul Gandhi to participate in Congress bus yatra in Telangana
  • Punjab govt releases Rs 112 78 crore under 'Aashirwad' scheme:Minister
  • UAE breaks barriers: child adoption on rise
  • Closure of tuition centres by govt endorsement of failures: Cong
Science Technology Share

Dengvaxia, a live recombinant tetravalent dengue vaccine developed by Sanofi Pasteur

Dengvaxia,  a live recombinant tetravalent dengue vaccine developed by Sanofi Pasteur

Kolkata, Dec 5 (UNI) There continues to be a strong public health need for effective preventive interventions against dengue, a disease caused by four viruses, termed serotypes 1-4.

One dengue vaccine has been licensed, Dengvaxia (also referred to as CYD-TDV), developed by Sanofi Pasteur. Dengvaxia is a live recombinant tetravalent dengue vaccine developed by Sanofi Pasteur, given as a 3-dose series on a 0/6/12 month schedule.

Dengvaxia is the first dengue vaccine to be licensed and has now been approved by 19 regulatory authorities for use in endemic areas in persons typically ranging from 9-45 (in some countries 9-60) years of age.

It has been introduced in two subnational programs in the Philippines and Brazil targeting about one million individuals. It is otherwise available on the private market in countries where there is a marketing authorization.

Dengvaxia has been evaluated in two Phase 3 clinical trials (CYD14 trial in five countries in Asia and CYD15 trial in five countries in Latin America). Together, these trials included over 30,000 participants aged 2 to 16 years.

Vaccine efficacy against confirmed dengue pooled across both trials was 59.2 per cent in the year following the primary series, and 79.1 per cent against severe dengue. Efficacy varied by serotype, by age at vaccination and serostatus at baseline (i.e., previous exposure to dengue prior to vaccination).

While efficacy was reported against hospitalized and severe dengue in Years 1 and 2 post-dose 1, an excess of cases of hospitalized and severe dengue cases in those receiving Dengvaxia was seen in Year 3 in some subgroups, although it is based on relatively small numbers of cases. Whether the increased risk was due to age or serostatus at baseline, which is highly correlated with age, could not be fully clarified with the available data at the time.

For subjects aged 9 and above, in the first 25 months of the phase 3 trials, there was a reduction in severe dengue by 93 per cent and a reduction in hospitalizations by 81 per

cent.

MORE UNI BM SJC

More News
Mosquito-packed drones ready to join fight against Zika

Mosquito-packed drones ready to join fight against Zika

20 Apr 2018 | 7:09 PM

United Nations, Apr 20 (UNI) Robotics may soon be a critical ally in the fight against disease-spreading bugs, a United Nations agency has said after a successful test releasing sterile mosquitos from aerial drones as part of efforts to suppress the insect that spreads Zika and other diseases.

 Sharesee more..
Evidence shows banning asbestos has no negative economic impact

Evidence shows banning asbestos has no negative economic impact

20 Apr 2018 | 11:56 AM

Kolkata, Apr 20 (UNI) Sound scientific evidence shows that any exposure to asbestos fibres poses significant health risks.

 Sharesee more..
Nadda directs for comprehensive strategy to tackle leprosy, TB

Nadda directs for comprehensive strategy to tackle leprosy, TB

17 Apr 2018 | 6:47 PM

New Delhi, Apr 17 (UNI) Union Minister for Health and Family Welfare JP Nadda directed for a comprehensive strategy for addressing incidence, prevalence and surveillance aspects to eliminate leprosy at district level and reviewed Tuberculosis Control Programme on Tuesday.

 Sharesee more..
Fortis Hospital performs Double Root Translocation surgery to cure 3-year-old Kashmiri boy

Fortis Hospital performs Double Root Translocation surgery to cure 3-year-old Kashmiri boy

14 Apr 2018 | 4:32 PM

New Delhi, Apr 14 (UNI A team of doctors at Fortis Memorial Research Institute (FMRI) recently performed a rare Double Root Translocation Surgery to cure three-year Mohammed Aasim, from Safapora, Ganderbal in Jammu and Kashmir recently.

 Sharesee more..
WHO and UNICEF issue new guidance to promote breastfeeding in health facilities globally

WHO and UNICEF issue new guidance to promote breastfeeding in health facilities globally

12 Apr 2018 | 2:25 PM

Kolkata, Apr 12 (UNI) WHO and UNICEF on Wednesday issued new ten-step guidance to
increase support for breastfeeding in health facilities that provide maternity and newborn
services.

 Sharesee more..
image